Information in the news releases is current on the date of the announcement, but is subject to change without prior notice.
December 27, 2010
EISAI COMMENCES ONLINE SALES OF FOOD WITH NUTRIENT FUNCTION CLAIMS IN JAPAN
Launches JUVELA ZEITAKU POLYPHENOL to Support the Health of the Over Fifty Population
December 21, 2010
EISAI RECEIVES APPROVAL FOR TWICE-DAILY DOSING OF PROTON PUMP INHIBITOR PARIET® FOR TREATMENT OF REFLUX ESOPHAGITIS
Offers New Option to Patients Unable to Obtain Satisfactory Relief with Conventional Proton Pump Inhibitor Treatment
December 21, 2010
EISAI SIGNS CHINA MARKETING AGREEMENT FOR ANTI-INFLAMMATORY ANALGESIC POULTICE HAOJISHI
December 16, 2010
EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION IN JAPAN FOR EMBOLIC BEAD E7040
December 14, 2010
Sanko Junyaku and Sekisui Medical Conclude Exclusive Japan Marketing Agreement for Influenza Test Kit RapidTesta® FLU Ⅱ
December 10, 2010
EISAI MARKS FULLY-FLEDGED ENTRY INTO JAPANESE ONCOLOGY MARKET WITH LAUNCH OF ANTICANCER AGENT TREAKISYM® INJECTION 100 MG
December 1, 2010
Pfizer and Eisai Launch New Website “Toutsu.jp”
First General Public-Oriented Portal Site Dedicated to Neural Pain
November 30, 2010
EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION IN JAPAN FOR INSOMNIA TREATMENT SEP-190
November 18, 2010
EISAI TO PROVIDE MEDICINE TO HELP WORLD HEALTH ORGANIZATION (WHO) COMBAT LYMPHATIC FILARIASIS EPIDEMIC
THE FIRST PUBLIC-PRIVATE PARTNERSHIP TO BE ESTABLISHED BETWEEN WHO AND A JAPANESE PHARMACEUTICAL COMPANY TO OVERCOME THE IMPACT OF A NEGLECTED TROPICAL DISEASE IN DEVELOPING COUNTRIES
November 17, 2010
EISAI AND FORMA THERAPEUTICS ENTER INTO BROAD DRUG DISCOVERY COLLABORATION
November 16, 2010
U.S. FDA APPROVES EISAI'S HALAVEN™ (ERIBULIN MESYLATE) INJECTION FOR TREATMENT OF METASTATIC BREAST CANCER
New Treatment Synthetically Derived From a Sea Sponge (Halichondria okadai) Demonstrated a Statistically Significant Improvement in Overall Survival in Late-Stage Metastatic Breast Cancer
November 10, 2010
LORCASERIN PHASE 3 CLINICAL TRIAL IN PATIENTS WITH TYPE 2 DIABETES SHOWS STATISTICALLY SIGNIFICANT WEIGHT LOSS
November 8, 2010
EISAI ANNOUNCES LAUNCH OF CRYSTAL VEIL COOL, A POSITIVELY CHARGED MENTHOL ALLERGEN SCREEN TOPICAL GEL THAT PROTECTS AGAINST POLLEN AND HOUSE DUST
November 1, 2010
Notice for objection to sale of shares held by untraceable shareholders
October 29, 2010
Abbott Japan and Eisai Receive Approval for Additional Indications of Humira®, a Fully Human Anti-TNFα Monoclonal Antibody, for the Treatment of Crohn's Disease and Ankylosing Spondylitis
October 28, 2010
Abbott Japan and Eisai have Cleared the Condition for Approval of Humira®, a Fully Human Anti-TNF-alpha Monoclonal Antibody, for Rheumatoid Arthritis in Terms of the All-Case Surveillance
October 28, 2010
EISAI TO WITHDRAW JAPAN MARKETING AUTHORIZATION APPLICATION FOR ANTIOBESITY AGENT KES524
October 27, 2010
New Indication Approved for Lyrica® Capsules
October 27, 2010
EISAI ANNOUNCES JAPAN APPROVAL OF ANTICANCER AGENT TREAKISYM®
October 23, 2010
FDA ISSUES COMPLETE RESPONSE LETTER FOR LORCASERIN NEW DRUG APPLICATION
October 7, 2010
MILESTONE RULING FOR ALZHEIMER'S DISEASE PATIENTS ANNOUNCED
NICE ISSUES NEW DRAFT GUIDANCE
September 30, 2010
Brain Factory and Eisai Conclude License Agreement for Ravuconazole Prodrug
September 29, 2010
Eisai and Anaeropharma Science Conclude Agreements Concerning the Novel Anticancer Agent APS001 and a Drug Delivery System Using Bifidobacterium Longum
September 17, 2010
FDA ACCEPTS ARICEPT® PATCH (DONEPEZIL TRANSDERMAL SYSTEM) NDA FOR REVIEW
September 17, 2010
EISAI PROVIDES UPDATE ON LORCASERIN FDA ADVISORY COMMITTEE MEETING
September 15, 2010
JAPANESE CLINICAL TRIALS CONFIRM SAFETY AND EFFICACY OF INSOMNIA TREATMENT SEP-190 EISAI PLANS TO SUBMIT MAA IN FISCAL 2010
September 7, 2010
SymBio and Eisai to Launch Symbenda® (Bendamustine Hydrochloride) in Singapore for the Treatment of Low-grade Non-Hodgkin's Lymphoma and Chronic Lymphatic Leukemia
September 3, 2010
EISAI TO LAUNCH RAPID-ACTING INSULIN SECRETAGOGUE GLUFAST® IN CHINA
September 2, 2010
EISAI ANNOUNCES THE START OF THE FIRST CLINICAL STUDY OF BAN2401, A NOVEL MONOCLONAL ANTIBODY TARGETING THE NEUROTOXIC PROTOFIBRILS BELIEVED TO CAUSE ALZHEIMER'S DISEASE
August 30, 2010
EISAI ANNOUNCES EXTENSION OF FDA REVIEW OF DRUG APPLICATION FOR INVESTIGATIONAL AGENT ERIBULIN MESYLATE
August 30, 2010
Abbott Japan and Eisai Submit Application for Additional Indication of Humira®, a Fully Human Anti-TNFα Monoclonal Antibody, for the Treatment of Juvenile Idiopathic Arthritis in Japan
August 24, 2010
EISAI ANNOUNCES POSITIVE RESULTS OF PHASE Ⅲ TRIAL FOR PERAMPANEL IN EPILEPSY
July 30, 2010
Continuation of Policy for Protection of the Company's Corporate Value and Common Interests of Shareholders (Shareholder Rights Plan)
July 24, 2010
EISAI ANNOUNCES U.S. FDA APPROVAL FOR NEW HIGHER DOSE ARICEPT® 23 MG TABLET FOR THE TREATMENT OF MODERATE-TO-SEVERE ALZHEIMER'S DISEASE
July 20, 2010
FDA ACCEPTS BANZEL® (RUFINAMIDE) ORAL SUSPENSION NDA FOR REVIEW
July 15, 2010
NEW ENGLAND JOURNAL OF MEDICINE PUBLISHES RESULTS OF TWO-YEAR BLOOM TRIAL SHOWING LORCASERIN CAUSED SIGNIFICANT WEIGHT LOSS AND IMPROVED MAINTENANCE OF WEIGHT LOSS
July 5, 2010
Notice on Determination of Details of Stock Options (Stock Acquisition Rights) to be Allotted
July 1, 2010
EISAI INC. ENTERS INTO MARKETING AND SUPPLY AGREEMENT WITH ARENA PHARMACEUTICALS FOR LORCASERIN, A POTENTIAL TREATMENT FOR OBESITY AND WEIGHT MANAGEMENT
June 29, 2010
EISAI INTRODUCES TRAVELMIN® 1, A ONCE-DAILY RAPIDLY DISINTEGRATING TABLET FOR PREVENTION AND ALLEVIATION OF MOTION SICKNESS
June 24, 2010
EISAI RECEIVES APPROVAL FOR ADDITIONAL INDICATION OF PROTON PUMP INHIBITOR PARIET® FOR NON-EROSIVE GERD IN JAPAN
June 23, 2010
EISAI'S INVESTIGATIONAL ANTICANCER AGENT ERIBULIN MESYLATE (E7389) RECEIVES PRIORITY REVIEW STATUS IN JAPAN
June 18, 2010
Approval of Additional Indications for Helicobacter pylori Eradication by Concomitant Therapy with Proton Pump Inhibitors
June 18, 2010
Notice on Allocation of Stock Options (Stock Acquisition Rights)
June 11, 2010
Pfizer, Eisai to launch postherpetic neuralgia drug Lyrica® Capsules on June 22
June 9, 2010
EISAI ENTERS INTO U.S. LICENSE AGREEMENT WITH HELSINN HEALTHCARE S.A. FOR NEW COMBINATION ANTIEMETIC AGENT
June 7, 2010
PHASE Ⅲ STUDY RESULTS SHOWED EISAI'S ERIBULIN MESYLATE SIGNIFICANTLY IMPROVED OVERALL SURVIVAL IN PATIENTS WITH LOCALLY RECURRENT OR METASTATIC BREAST CANCER
Global EMBRACE Study Compared Eribulin to Treatment of Physician's Choice
June 3, 2010
FDA ACCEPTS FOR REVIEW EISAI'S NDA FOR PROTON PUMP INHIBITOR ACIPHEX® EXTENDED-RELEASE 50 mg FORMULATION
June 1, 2010
EISAI'S INVESTIGATIONAL ANTICANCER AGENT ERIBULIN MESYLATE (E7389) RECEIVES PRIORITY REVIEW STATUS IN THE UNITED STATES
May 24, 2010
EISAI TO PRESENT NEW RESEARCH ON ONCOLOGY PIPELINE, PORTFOLIO AT ASCO ANNUAL MEETING
HIGHLIGHTS INCLUDE NEW PHASE Ⅲ DATA ON INVESTIGATIONAL ANTICANCER AGENT ERIBULIN IN LOCALLY RECURRENT OR METASTATIC BREAST CANCER
May 20, 2010
EISAI OPENS NEW PARENTERAL ONCOLOGY DRUG PRODUCTION FACILTY AT ITS U.S. PLANT IN NORTH CAROLINA
May 14, 2010
Issuance of Stock Acquisition Rights for the Purpose of Granting Stock Options to the Company's Employees
May 13, 2010
EISAI RECEIVES APPROVAL FOR ADDITIONAL INDICATION OF ANTI-ARRHYTHMIC AGENT TAMBOCOR® TABLETS FOR TACHYARRHYTHMIA IN PEDIATRIC PATIENTS IN JAPAN
May 11, 2010
EISAI ESTABLISHES NEW SALES SUBSIDIARY IN CANADA
May 7, 2010
EISAI TO INITIATE JAPAN CLINICAL TRIAL OF ANTIEPILEPTIC AGENT RUFINAMIDE IN PATIENTS WITH LENNOX-GASTAUT SYNDROME
May 6, 2010
EISAI SUBMITS APPLICATION IN JAPAN FOR TWICE-DAILY DOSING OF ITS PROTON PUMP INHIBITOR PARIET® FOR THE TREATMENT OF REFLUX ESOPHAGITIS
April 16, 2010
Lyrica® has been approved for treatment of postherpetic neuralgia
April 16, 2010
EISAI SIGNS LICENSE AGREEMENT WITH ALMIRALL FOR THE DEVELOPMENT, MANUFACTURING AND MARKETING OF CINITAPRIDE IN CHINA
March 31, 2010
Eisai Submits Regulatory Applications for Investigational Anticancer Agent Eribulin Mesylate (E7389) in Japan, the United States and Europe
March 29, 2010
Notice Concerning Shelf Registration for Issuance of Stock Options
March 26, 2010
Eisai to Continue Eritoran (E5564) Phase Ⅲ Severe Sepsis Trial
March 12, 2010
FDA Approves Five-Day Dosing Regimen for Dacogen®
New Regimen Offers a New Outpatient Dosing Option for Myelodysplastic Syndromes
March 9, 2010
Eisai Breaks Ground for New Morphotek Pilot Plant
March 2, 2010
Eisai Introduces Travelmin® Churop Lemon Flavor
A New Flavor of its Drop-type Motion Sickness Remedy
February 24, 2010
Eisai Launches REVOVIR® in the Philippines for the Treatment of Chronic Hepatitis B
January 20, 2010
Fully Human Monoclonal Anti-TNF-α Antibody HUMIRA® Receives Approval as Japan's First Biological Agent for Psoriasis
January 19, 2010
Eisai Group Contributes to Haiti Earthquake Relief Efforts
January 14, 2010
Eisai Submits Application for Additional Indication of Anti-arrhythmic Agent Tambocor® Tablets for Tachyarrhythmia in Paediatric Patients in Japan
January 12, 2010
Eisai Introduces New Chocola BB Series Pharmaceutical Product “Chocola BB® Royal T”
Vitamin B2, Royal Jelly and Taurine Containing Tablets Alleviate Symptoms of Daily Fatigue
January 7, 2010
Eisai Completes Acquisition of AkaRx, Inc. in the United States
